MNPR

Monopar Therapeutics Inc

Sep 16 • 04:00PM ET

57.00

+2.51 4.61 %

Healthcare • Biotechnology • USA • NASD

Peers: FATE MCRB AFMD ADAP EYPT ADVM CYCN CTMX XBIT CBIO

| Held by: IWM IWO VXF VTWO IWC GSSC VTWG RSSL AVSC URTY

Index	RUT	P/E	-	EPS (ttm)	-3.85	Insider Own	35.90%	Shs Outstand	6.13M	Perf Week	26.86%
Market Cap	351.69M	Forward P/E	-	EPS next Y	-3.64	Insider Trans	-3.31%	Shs Float	3.95M	Perf Month	59.62%
Enterprise Value	298.55M	PEG	-	EPS next Q	-0.46	Inst Own	50.96%	Short Float	3.45%	Perf Quarter	66.57%
Income	-17.31M	P/S	-	EPS this Y	57.56%	Inst Trans	16.47%	Short Ratio	3.18	Perf Half Y	66.52%
Sales	0.00M	P/B	6.69	EPS next Y	-108.66%	ROA	-56.71%	Short Interest	0.14M	Perf YTD	159.09%
Book/sh	8.52	P/C	6.60	EPS next 5Y	9.37%	ROE	-59.38%	52W High	54.54 4.51%	Perf Year	1343.04%
Cash/sh	8.63	P/FCF	-	EPS past 3/5Y	-4.06% -15.56%	ROIC	-33.11%	52W Low	3.65 1461.64%	Perf 3Y	555.17%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	10.15% 9.18%	Perf 5Y	106.52%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-66.95%	Oper. Margin	-	ATR (14)	3.80	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	33.94	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	74.23	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	33.94	EPS Q/Q	28.41%	SMA20	44.53%	Beta	1.24	Target Price	82.00
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	42.04%	Rel Volume	1.78	Prev Close	54.49
Employees	16	LT Debt/Eq	0.00	Earnings	Aug 12 BMO	SMA200	59.77%	Avg Volume	42.89K	Price	57.00
IPO	Dec 19, 2019	Option/Short	No / Yes	EPS/Sales Surpr.	23.63% -	Trades		Volume	76,445	Change	4.61%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-09-25	Initiated	BTIG Research	Buy	$87
Sep-03-25	Initiated	Raymond James	Strong Buy	$80
Sep-03-25	Initiated	Oppenheimer	Outperform	$77
Aug-26-25	Resumed	H.C. Wainwright	Buy	$70
Jul-07-25	Initiated	Cantor Fitzgerald	Overweight	$74
Jun-23-25	Initiated	Chardan Capital Markets	Buy	$60
Mar-19-25	Resumed	Piper Sandler	Overweight	$76
Jan-10-25	Initiated	Piper Sandler	Overweight	$72
Oct-11-24	Initiated	Rodman & Renshaw	Buy	$50
Jan-28-21	Initiated	ROTH Capital	Buy	$49

Sep-15-25 01:15PM	Why Monopar Therapeutics, A Top 1% Biotech Stock, Just Surged Into A Breakout (Investor's Business Daily) +10.71%
Sep-14-25 08:00AM	Monopar to Present New Long-Term Neurological Efficacy and Safety Data for ALXN1840 in Wilson Disease at the 150th American Neurological Association Annual Meeting (GlobeNewswire)
Sep-03-25 08:00AM	Monopar Announces Abstract Accepted with Distinction for Oral and Poster Presentations at the Upcoming American Neurological Association 2025 Annual Meeting (GlobeNewswire) +6.72%
Aug-12-25 08:00AM	Monopar Therapeutics Reports Second Quarter 2025 Financial Results and Recent Developments (GlobeNewswire) +14.55%
Jun-26-25 03:24PM	Chardan Initiates Coverage of Monopar Therapeutics (MNPR) Stock, Gives Buy (Insider Monkey) +9.68%
09:55AM	Loading…
Jun-11-25 09:55AM	Wall Street Analysts Predict a 51.26% Upside in Monopar Therapeutics (MNPR): Here's What You Should Know (Zacks)
07:00AM	Monopar and EDNOC Announce Expanded Access Program for MNPR-101-Zr and MNPR-101-Lu in Advanced Cancers (GlobeNewswire)
Jun-06-25 09:40AM	Salesforce initiated, Dollar Tree upgraded: Wall Streets top analyst calls (TipRanks)
Jun-03-25 07:00AM	Monopar Therapeutics Announces Inclusion in the Russell 3000 and Russell 2000 Indexes (GlobeNewswire) +7.00%
May-13-25 08:00AM	Monopar Therapeutics Reports First Quarter 2025 Financial Results and Recent Developments (GlobeNewswire)
May-07-25 02:30AM	Monopar Presents ALXN1840 Late-Breaker Data at EASL 2025 (GlobeNewswire)
Apr-30-25 05:37AM	Why Monopar Therapeutics Inc. (MNPR) is Surging in 2025 (Insider Monkey)
Apr-29-25 08:00AM	Monopar Announces ALXN1840 Data Selected for Late-Breaker Presentation at EASL Congress 2025 (GlobeNewswire)
Mar-31-25 08:00AM	Monopar Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Developments (GlobeNewswire) -9.72%
Mar-21-25 08:50AM	Here's Why Momentum in Monopar Therapeutics (MNPR) Should Keep going (Zacks) -10.59%
07:22PM	Loading…
Feb-03-25 07:22PM	Why Monopar Therapeutics Inc (MNPR) Is Skyrocketing So Far In 2025 (Insider Monkey) +10.22%
Jan-23-25 01:10PM	Rosalind Franklin University's Helix 51 Incubator Welcomes Monopar Therapeutics (PR Newswire) +16.78%
07:06AM	Monopar Therapeutics price target raised to $40 from $22 at H.C. Wainwright (TipRanks)
Dec-31-24 02:36AM	These 2 Monster Growth Stocks Skyrocketed Over 1,000% This Year Heres What Analysts Expect in 2025 (TipRanks) -7.76%
Dec-20-24 09:00AM	Monopar Therapeutics Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants (GlobeNewswire) +8.53%
Dec-05-24 04:21PM	Monopar Announces First Patient Dosed with its Novel Therapeutic Radiopharmaceutical MNPR-101-Lu (GlobeNewswire) -14.84%
Dec-03-24 08:00AM	Monopar to Present at the 36th Annual Piper Sandler Healthcare Conference (GlobeNewswire) +5.27%
Nov-08-24 08:00AM	Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments (GlobeNewswire) +7.31%
Oct-30-24 01:42PM	Monopar Therapeutics Inc. Announces Closing of $19.2 Million Public Offering of Common Stock (GlobeNewswire) -9.50%
Oct-28-24 09:15PM	Monopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common Stock (GlobeNewswire) +5.32% -9.09%
04:00PM	Monopar Therapeutics Inc. Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Oct-25-24 07:31AM	Monopar Therapeutics Secures License for Wilson Disease Treatment (TipRanks) -48.16%
Oct-24-24 07:00AM	Monopar Announces Agreement with Alexion, AstraZeneca Rare Disease For Late-Stage Wilson Disease Drug Candidate (GlobeNewswire) +605.40%
Oct-22-24 08:00AM	Monopar Presents Encouraging Human Clinical Dosimetry Data on its uPAR Program at EANM 2024 (GlobeNewswire)
Oct-16-24 08:28AM	Monopar Therapeutics Expands Portfolio with New Patent Filing (TipRanks)
08:00AM	Loading…
Oct-15-24 08:00AM	Monopar Expands Radiopharma Intellectual Property Portfolio with Patent Filing on New Compounds and Linkers (GlobeNewswire)
Oct-08-24 08:30AM	Monopar Therapeutics Launches Phase 1a uPAR-Targeted Cancer Trial (TipRanks) +5.12%
Oct-07-24 08:00AM	Monopar Initiates Clinical Trial of Novel uPAR-Targeted Radiopharmaceutical Therapy in Advanced Cancers (GlobeNewswire) +10.20%
Sep-12-24 08:00AM	Monopar Announces Positive Early Human Clinical Data Validating the Tumor Targeting Ability of MNPR-101-Zr (GlobeNewswire) +64.58%
Sep-04-24 08:00AM	Monopar to Participate in the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Aug-27-24 04:05PM	Monopar Regains Compliance with Nasdaq Minimum Bid Price Rule (GlobeNewswire) -8.40% -5.83%
Aug-21-24 08:00AM	Monopar Receives Clearance to Proceed with Phase 1 Therapeutic Trial of Novel Radiopharmaceutical in Advanced Cancers (GlobeNewswire)
Aug-14-24 08:00AM	Monopar Announces Initial Data for First Patient Dosed in Radiopharma Phase 1 Clinical Trial of MNPR-101-Zr (GlobeNewswire) -5.79%
Aug-12-24 12:24PM	Upcoming Stock Splits This Week (August 12 to August 16) Stay Invested (TipRanks) +6.56%
Aug-09-24 02:53PM	MNPR Stock Earnings: Monopar Therapeutics Misses EPS for Q2 2024 (InvestorPlace) -19.64%
08:00AM	Monopar Therapeutics Reports Second Quarter 2024 Financial Results and Recent Developments (GlobeNewswire)
08:00AM	Monopar Therapeutics Announces 1-for-5 Reverse Stock Split (GlobeNewswire)
Jul-09-24 07:00AM	Monopar Announces First Patient Enrolled in First-in-Human Phase 1 Trial for Its Novel Radiopharmaceutical MNPR-101-Zr (GlobeNewswire)
Jun-25-24 08:00AM	Monopar Announces MNPR-101-RIT Abstract Accepted as a Top-Rated Oral Presentation at EANM'24 (GlobeNewswire)
Jun-11-24 07:30AM	Monopar and NorthStar Amend & Extend Collaboration (GlobeNewswire) +5.22%
Jun-10-24 08:00AM	Monopar Presents Data Showcasing the Appeal of uPAR as a Radiopharma Cancer Target and of its lead Clinical Program at the 2024 SNMMI Annual Meeting (GlobeNewswire)
Jun-05-24 06:15AM	Penny Stocks That Insiders Are Loading Up On: 3 Names to Watch Closely (InvestorPlace)
May-24-24 08:00AM	Monopar Announces CFO Succession (GlobeNewswire)
May-17-24 09:55AM	Bears are Losing Control Over Monopar Therapeutics (MNPR), Here's Why It's a 'Buy' Now (Zacks)
May-09-24 01:55PM	MNPR Stock Earnings: Monopar Therapeutics Beats EPS for Q1 2024 (InvestorPlace) -5.19%
07:00AM	Monopar Therapeutics Reports First Quarter 2024 Financial Results and Strategic Focus on its Radiopharma Pipeline (GlobeNewswire)
Apr-18-24 08:00AM	Monopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting (GlobeNewswire)
Apr-16-24 08:00AM	Monopar Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization Findings (GlobeNewswire)
Apr-10-24 08:00AM	Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients (GlobeNewswire) +8.36%
Apr-04-24 09:55AM	Monopar Therapeutics (MNPR) Could Find a Support Soon, Here's Why You Should Buy the Stock Now (Zacks)
Apr-03-24 12:00PM	All You Need to Know About Monopar Therapeutics (MNPR) Rating Upgrade to Buy (Zacks)
Mar-28-24 11:53AM	MNPR Stock Earnings: Monopar Therapeutics Beats EPS for Q4 2023 (InvestorPlace) -7.60%
07:00AM	Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Developments (GlobeNewswire)
Mar-05-24 07:00AM	Monopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma Program (GlobeNewswire) +7.06%
Feb-27-24 07:00AM	Monopar Provides Update on MNPR-101-Zr Radiopharma Clinical Trial (GlobeNewswire) -10.37%
Feb-23-24 11:55AM	5 Best Rising Penny Stocks To Buy (Insider Monkey) +16.07%
Feb-22-24 07:00AM	Monopar Announces Promising Preclinical Data for its MNPR-101 Radiopharma Program Targeting Advanced Cancers (GlobeNewswire) +96.49%
Feb-20-24 08:00AM	Monopar Receives Clearance to Proceed with First-in-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced Cancers (GlobeNewswire) +95.27%
Nov-09-23 08:37AM	Monopar Therapeutics Inc Reports Q3 2023 Financial Results and Progress in Clinical Programs (GuruFocus.com)
07:00AM	Monopar Therapeutics Reports Third Quarter 2023 Financial Results and Recent Developments (GlobeNewswire)
Nov-01-23 07:00AM	Monopar Presents Data Showing Tumor Reduction Benefit of Camsirubicin from Ongoing Phase 1b at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting (GlobeNewswire) +27.91%
Oct-10-23 07:00AM	Monopar to Participate in the Roth MKM 2023 Healthcare Opportunities Conference (GlobeNewswire) -5.96%
Sep-05-23 07:00AM	Monopar to Participate in the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-10-23 07:00AM	Monopar Therapeutics Reports Second Quarter 2023 Financial Results and Recent Developments (GlobeNewswire)
Aug-08-23 07:00AM	Monopar Provides Encouraging Camsirubicin Clinical Data Update (GlobeNewswire) +15.22%
Jul-11-23 07:00AM	Monopar Announces MNPR-101 Radiopharma Collaboration Agreement with National University of Singapore (GlobeNewswire)
Jun-21-23 07:00AM	Monopar to Participate in the Radiopharma Forum by the Lake 2023 (GlobeNewswire)
Jun-14-23 07:00AM	Monopar to Participate in the Maxim Groups Healthcare Virtual Conference (GlobeNewswire)
Jun-01-23 07:00AM	Monopar Announces Encouraging Camsirubicin Phase 1b Trial Update (GlobeNewswire) +7.36%
May-29-23 09:55AM	Monopar Therapeutics Inc. (MNPR) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? (Zacks)
May-11-23 07:00AM	Monopar Therapeutics Reports First Quarter 2023 Financial Results and Recent Developments (GlobeNewswire) -6.58%
Apr-19-23 09:55AM	Monopar Therapeutics Inc. (MNPR) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
Mar-28-23 01:40PM	Monopar Therapeutics Shelves Development Of Validive For Radiation Therapy-Related Complication (Benzinga) -51.34%
07:00AM	Monopar to Present at the Jefferies Radiopharma Innovation Summit (GlobeNewswire)
Mar-27-23 05:00PM	Monopar Announces Result of Interim Analysis of Phase 2b/3 VOICE Trial Evaluating Validive for Severe Oral Mucositis (GlobeNewswire)
Mar-23-23 07:00AM	Monopar Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Developments (GlobeNewswire)
Mar-07-23 07:00AM	Monopar to Present at the 35th Annual Roth Conference (GlobeNewswire)
Feb-27-23 07:00AM	Monopar and NorthStar Announce Expanded Radiopharma Program, Positive Preclinical Results, and Visibility Toward Human Trials (GlobeNewswire)
Feb-14-23 12:46PM	What's Going On With Monopar Therapeutics Shares Today? (Benzinga)
07:00AM	Monopar Announces Camsirubicin Clinical Program Update - Improved Side Effect Profile Seen to Date Compared to Doxorubicin (GlobeNewswire)
Feb-05-23 08:38AM	We're Keeping An Eye On Monopar Therapeutics' (NASDAQ:MNPR) Cash Burn Rate (Simply Wall St.)
Jan-26-23 07:00AM	Monopar Announces Projected Timeline of Upcoming Q1 2023 Data Events for Validive, Camsirubicin, and MNPR-101 RIT (GlobeNewswire)
Jan-18-23 07:00AM	Monopar Announces Successful Advancement of Camsirubicin Phase 1b Clinical Trial Past Fourth Cohort, Escalates Next to 650mg/m2 (GlobeNewswire)
Dec-12-22 07:00AM	Monopar Announces Promising MNPR-202 Data from Ongoing National University of Singapore Collaboration (GlobeNewswire) -18.97%
Nov-18-22 01:10PM	Monopar Therapeutics (MNPR) Up On Soft Tissue Sarcoma Study Data (Zacks) -6.42%
09:55AM	Monopar Therapeutics Inc. (MNPR) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
Nov-16-22 10:09AM	Monopar Therapeutics Highlights Encouraging Data From Early-Stage Soft Tissue Cancer Study (Benzinga)
07:00AM	Monopar Announces Encouraging Clinical Data from Ongoing Camsirubicin Phase 1b Trial (GlobeNewswire)
Nov-10-22 08:00AM	Monopar Therapeutics Reports Third Quarter 2022 Financial Results and Recent Program Developments (GlobeNewswire) -24.83%
Oct-27-22 08:00AM	Monopar Announces Timeline of Upcoming Data Events for Validive, Camsirubicin, and MNPR-202 (GlobeNewswire)
Oct-19-22 08:00AM	Monopar Announces Presentation Selected for 2022 American Society of Hematology (ASH) 64th Annual Meeting (GlobeNewswire)
Oct-12-22 08:00AM	Monopar Announces Presentation Selected for 2022 Connective Tissue Oncology Society (CTOS) Annual Meeting (GlobeNewswire)
Oct-05-22 08:50AM	Monopar's stock gains 13% after completing enrollment for an experimental therapy for cancer patients (MarketWatch)
08:00AM	Monopar Announces Completion of Phase 2b Enrollment and Commencement of Phase 3 Enrollment in its VOICE Trial for Severe Oral Mucositis (GlobeNewswire)
Sep-28-22 08:00AM	Monopar to Present at Roth Inaugural Healthcare Opportunities Conference (GlobeNewswire)

Monopar Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing proprietary therapeutics for cancer patients. It also focuses on building a drug development pipeline through the licensing, and acquisition of therapeutics in late preclinical and clinical development stages. The company was founded by Chandler Drew Robinson, Christopher M. Starr and Andrew P. Mazar in December 2014 and is headquartered in Wilmette, IL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Tsuchimoto Kim R	Director	Jul 14 '25	Sale	40.00	8,904	356,171	11,486	Jul 16 09:06 PM
STARR CHRISTOPHER M	Director	Jul 14 '25	Sale	40.00	16,800	672,020	5,173	Jul 16 09:03 PM
Robinson Chandler	Chief Executive Officer	Jul 14 '25	Sale	40.00	16,800	672,020	73,472	Jul 16 09:02 PM
STARR CHRISTOPHER M	Director	Jul 14 '25	Proposed Sale	40.00	16,800	672,000		Jul 14 12:29 PM
Tsuchimoto Kim R	Director	Jul 14 '25	Proposed Sale	40.00	8,904	356,160		Jul 14 12:26 PM
Robinson Chandler	Officer	Jul 14 '25	Proposed Sale	40.00	16,800	672,000		Jul 14 12:21 PM
Tactic Pharma LLC	10% Owner	Apr 02 '25	Sale	35.00	33,334	1,166,690	822,255	Apr 04 07:27 PM
Tactic Pharma LLC	10% Owner	Apr 02 '25	Proposed Sale	35.00	33,334	1,166,806		Apr 02 11:45 AM
Radhakrishnan Karthik	Chief Financial Officer	Oct 28 '24	Buy	16.25	1,550	25,188	1,550	Oct 30 04:17 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MNPR

Monopar Therapeutics Inc

Upgrade your FINVIZ experience